

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
23 September 2004 (23.09.2004)

PCT

(10) International Publication Number
WO 2004/081011 A1

(51) International Patent Classification⁷: **C07D 487/04**,
519/00, A61K 31/5025, A61P 3/10, 17/06, 19/02, 37/00

(21) International Application Number:
PCT/GB2004/001008

(22) International Filing Date: 10 March 2004 (10.03.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0305876.5 14 March 2003 (14.03.2003) GB
0319429.7 19 August 2003 (19.08.2003) GB

(71) Applicant (for all designated States except US): **AVIDEX LIMITED** [GB/GB]; 57 C Milton Park, Abingdon, Oxfordshire OX14 4RX (GB).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **MATHEWS, Ian, Richard** [GB/GB]; Avidex Limited, 57 C Milton Park, Abingdon, Oxfordshire OX14 4RX (GB).

(74) Agent: **WALLS, Alan, James**; Avidex Limited, 57C Milton Park, Abingdon, Oxfordshire OX14 4RX (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GII, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: IMMUNOMODULATING HETEROCYCLIC COMPOUNDS



(57) Abstract: Compounds of formula (I) are inhibitors of CD80 and useful in immunomodulation therapy: wherein R₁ and R₃ independently represent H; F; Cl; Br; -NO₂; -CN; C₁-C₆ alkyl optionally substituted by F or Cl; or C₁-C₆ alkoxy optionally substituted by F; R₄ represents a carboxylic acid group (-COOH) or an ester thereof, or -C(=O)NR₆R₇, -NR₇C(=O)R₆, -NR₇C(=O)OR₆, -NHC(=O)NR₇R₆ or -NHC(=S)NR₇R₆ wherein R₆ represents H, or a radical of formula - (Alk)_m-Q wherein m is 0 or 1, Alk is an optionally substituted divalent straight or branched C₁-C₁₂ alkylene, or C₂-C₁₂ alkenylene, or C₂-C₁₂ alkynylene radical or a divalent C₃-C₁₂ carbocyclic radical, any of which radicals may contain one or more -O-, -S- or -N(R₈)- links wherein R₈ represents H or C₁-C₄ alkyl, C₃-C₄ alkenyl, C₃-C₄ alkynyl, or C₃-C₆ cycloalkyl, and Q represents H; -NR₉R₁₀ wherein R₉ and R₁₀ independently represent H; C₁-C₄ alkyl; C₃-C₄ alkenyl; C₃-C₄ alkynyl; C₃-C₆ cycloalkyl; an ester group; an optionally substituted carbocyclic or heterocyclic group; or R₉ and R₁₀ form a ring when taken together with the nitrogen to which they are attached, which ring is optionally substituted; and R₇ represents H or C₁-C₆ alkyl; or when taken together with the atom or atoms to which they are attached R₆ and R₇ form an optionally substituted monocyclic heterocyclic ring having 5, 6 or 7 ring atoms; and X represents a bond or a divalent radical of formula - (Z)_n-(Alk)- or - (Alk)-(Z)_n- wherein Z represents -O-, -S- or -NH-, Alk is as defined in relation to R₆ and n is 0 or 1.

WO 2004/081011 A1

Immunomodulating Heterocyclic Compounds

The present invention relates to novel heterocyclic compounds, to methods for their preparation, to compositions containing them, and to methods and use
5 for clinical treatment of medical conditions which may benefit from immunomodulation, e.g. autoimmune disease, rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosus and psoriasis. More particularly the present invention relates to novel heterocyclic compounds, which are CD80 antagonists capable of inhibiting the
10 interactions between CD80 and CD28, useful for immuno-inhibition.


Background to the Invention

The immune system possesses the ability to control the homeostasis between the activation and inactivation of lymphocytes through various regulatory
15 mechanisms during and after an immune response. Among these are mechanisms that specifically inhibit and/or turn off an immune response. Thus, when an antigen is presented by MHC molecules to the T-cell receptor, the T-cells become properly activated only in the presence of additional co-stimulatory signals. In the absence of these accessory signals there is no
20 lymphocyte activation and either a state of functional inactivation termed anergy or tolerance is induced, or the T-cell is specifically deleted by apoptosis.

One such co-stimulatory signal involves interaction of CD80 on specialised
25 antigen-presenting cells with CD28 on T-cells, and this signal has been demonstrated to be essential for full T-cell activation. (Lenschow *et al.* (1996) *Annu. Rev. Immunol.*, **14**, 233-258). It would therefore be desirable to provide compounds which inhibit this CD80/CD28 interaction.

Detailed Description of the Invention

30 According to the present invention there is provided a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt, hydrate or solvate thereof:



wherein

R_1 and R_3 independently represent H; F; Cl; Br; $-\text{NO}_2$; $-\text{CN}$; $\text{C}_1\text{-C}_6$ alkyl optionally substituted by F or Cl; or $\text{C}_1\text{-C}_6$ alkoxy optionally substituted by F;

R_4 represents a carboxylic acid group ($-\text{COOH}$) or an ester thereof, or $-\text{C}(=\text{O})\text{NR}_6\text{R}_7$, $-\text{NR}_7\text{C}(=\text{O})\text{R}_6$, $-\text{NR}_7\text{C}(=\text{O})\text{OR}_6$, $-\text{NHC}(=\text{O})\text{NR}_7\text{R}_6$ or $-\text{NHC}(=\text{S})\text{NR}_7\text{R}_6$ wherein

R_6 represents H, or a radical of formula $-(\text{Alk})_m\text{-Q}$ wherein

m is 0 or 1

Alk is an optionally substituted divalent straight or branched $\text{C}_1\text{-C}_{12}$ alkylene, or $\text{C}_2\text{-C}_{12}$ alkenylene, or $\text{C}_2\text{-C}_{12}$ alkynylene radical or a divalent $\text{C}_3\text{-C}_{12}$ carbocyclic radical, any of which radicals may contain one or more $-\text{O}-$, $-\text{S}-$ or $-\text{N}(\text{R}_8)-$ links wherein R_8 represents H or $\text{C}_1\text{-C}_4$ alkyl, $\text{C}_3\text{-C}_4$ alkenyl, $\text{C}_3\text{-C}_4$ alkynyl, or $\text{C}_3\text{-C}_6$ cycloalkyl, and


Q represents H; $-\text{NR}_9\text{R}_{10}$ wherein R_9 and R_{10} independently represents H; $\text{C}_1\text{-C}_4$ alkyl; $\text{C}_3\text{-C}_4$ alkenyl; $\text{C}_3\text{-C}_4$ alkynyl; $\text{C}_3\text{-C}_6$ cycloalkyl; an ester group; an optionally substituted carbocyclic or heterocyclic group; or R_9 and R_{10} form a ring when taken together with the nitrogen to which they are attached, which ring is optionally substituted; and

R_7 represents H or $\text{C}_1\text{-C}_6$ alkyl; or when taken together with the atom or atoms to which they are attached R_6 and R_7 form an optionally

substituted monocyclic heterocyclic ring having 5, 6 or 7 ring atoms;
and

X represents a bond or a divalent radical of formula $-(Z)_n-(Alk)-$ or
5 $-(Alk)-(Z)_n-$ wherein Z represents $-O-$, $-S-$ or $-NH-$, Alk is as defined in
relation to R_6 and n is 0 or 1.

Compounds (I) may exist in the form of tautomers, such as (I¹) and (I²):



Hereafter, the compounds of the invention may be represented and referred to
in any tautomeric form (I), and it is to be understood that any and all
tautomeric forms of structure (I), in particular (I¹) and (I²), are included in the
invention.

Compounds of general formula (I) are CD80 antagonists. They inhibit the
interaction between CD80 and CD28 and thus the activation of T cells,
thereby modulating the immune response.

Accordingly the invention also includes:

(i) a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof for use in the treatment of conditions which benefit from immunomodulation, and in particular for immuno-inhibition.

(ii) the use of a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof in the manufacture of a medicament for the treatment of conditions which benefit from immunomodulation, and in particular for immuno-inhibition.

(iii) a method of immunomodulation, and in particular immuno-inhibition, in mammals, including humans, comprising administration to a mammal in need of such treatment an immunomodulatory effective dose of a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof.

(iv) a pharmaceutical or veterinary composition comprising a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof together with a pharmaceutically or veterinarily acceptable excipient or carrier.

Conditions which benefit from immunomodulation include:

Acute disseminated encephalomyelitis

Adrenal insufficiency

Allergic angiitis and granulomatosis

Amyloidosis

Ankylosing spondylitis

Asthma

Autoimmune Addison's disease

Autoimmune alopecia

Autoimmune chronic active hepatitis

Autoimmune haemolytic anaemia

Autoimmune Neutrogena

Autoimmune thrombocytopenic purpura

Behçet's disease

- Cerebellar degeneration
- Chronic active hepatitis
- Chronic inflammatory demyelinating polyradiculoneuropathy
- Chronic neuropathy with monoclonal gammopathy
- 5 Classic polyarteritis nodosa
- Congenital adrenal hyperplasia
- Cryopathies
- Dermatitis herpetiformis
- Diabetes
- 10 Eaton-Lambert myasthenic syndrome
- Encephalomyelitis
- Epidermolysis bullosa acquisita
- Erythema nodosa
- Gluten-sensitive enteropathy
- 15 Goodpasture's syndrome
- Guillain-Barre syndrome
- Hashimoto's thyroiditis
- Hyperthyroidism
- Idiopathic hemochromatosis
- 20 Idiopathic membranous glomerulonephritis
- Isolated vasculitis of the central nervous system
- Kawasaki's disease
- Minimal change renal disease
- Miscellaneous vasculitides
- 25 Mixed connective tissue disease
- Multifocal motor neuropathy with conduction block
- Multiple sclerosis
- Myasthenia gravis
- Opsoclonus-myoclonus syndrome
- 30 Pemphigoid
- Pemphigus
- pernicious anaemia
- Polymyositis/dermatomyositis
- Post-infective arthritides

- Primary biliary sclerosis
- Psoriasis
- Reactive arthritides
- Reiter's disease
- 5 Retinopathy
- Rheumatoid arthritis
- Sclerosing cholangitis
- Sjögren's syndrome
- Stiff-man syndrome
- 10 Subacute thyroiditis
- Systemic lupus erythematosus
- Systemic necrotizing vasculitides
- Systemic sclerosis (scleroderma)
- Takayasu's arteritis
- 15 Temporal arteritis
- Thromboangiitis obliterans
- Type I and type II autoimmune polyglandular syndrome
- Ulcerative colitis
- Uveitis
- 20 Wegener's granulomatosis

As used herein, the term "ester" refers to a group of the form $-\text{COOR}$, wherein R is a radical notionally derived from the alcohol ROH. Examples of ester groups include the physiologically hydrolysable esters such as the methyl, ethyl, n- and iso-propyl, n-, sec- and tert-butyl, and benzyl esters.

As used herein the term "alkylene" refers to a straight or branched alkyl chain having two unsatisfied valencies, for example $-\text{CH}_2-$, $-\text{CH}_2\text{CH}_2-$, $-\text{CH}_2\text{CH}_2\text{CH}_2-$, $-\text{CH}(\text{CH}_3)\text{CH}_2-$, $-\text{CH}(\text{CH}_2\text{CH}_3)\text{CH}_2\text{CH}_2\text{CH}_2-$, and $-\text{C}(\text{CH}_3)_3$.

30

As used herein the term "alkenylene" refers to a straight or branched alkenyl chain having two unsatisfied valencies, for example $-\text{CH}=\text{CH}-$, $-\text{CH}_2\text{CH}=\text{CH}-$, $-\text{C}(\text{CH}_3)=\text{CH}-$, and $-\text{CH}(\text{CH}_2\text{CH}_3)\text{CH}=\text{CHCH}_2-$.

As used herein the term "alkynylene" refers to a straight or branched alkynyl chain having two unsatisfied valencies, for example $\text{—C}\equiv\text{C—}$, $\text{—CH}_2\text{C}\equiv\text{C—}$, and $\text{—CH(CH}_2\text{CH}_3\text{)C}\equiv\text{CCH}_2\text{—}$.

- 5 Unless otherwise specified in the context in which it occurs, the term "substituted" as applied to any moiety herein means substituted with at least one substituent, selected from, for example, (C₁-C₆)alkyl, (C₁-C₆)alkenyl, (C₂-C₆)alkynyl, fluoro-substituted(C₁-C₆)alkyl, fluoro-substituted(C₁-C₆)alkenyl, fluoro-substituted(C₂-C₆)alkynyl, (C₁-C₆)alkoxy and fluoro-substituted(C₁-
- 10 C₆)alkoxy (including the special case where a ring is substituted on adjacent ring C atoms by alkylenedioxy such as methylenedioxy or ethylenedioxy), (C₁-C₆)alkylthio, phenyl, benzyl, phenoxy, benzyloxy, hydroxy, mercapto, amino, fluoro, chloro, bromo, cyano, nitro, oxo, —COOH , $\text{—SO}_2\text{OH}$, —CONH_2 , $\text{—SO}_2\text{NH}_2$, —COR^A , —COOR^A , $\text{—SO}_2\text{OR}^A$, —NHCOR^A , $\text{—NHSO}_2\text{R}^A$, —CONHR^A , $\text{—SO}_2\text{NHR}^A$, —NHR^A , $\text{—NR}^A\text{R}^B$, $\text{—CONR}^A\text{R}^B$ or $\text{—SO}_2\text{NR}^A\text{R}^B$ wherein R^A and R^B are
- 15 independently a (C₁-C₆)alkyl or (C₂-C₆)alkoxy group or a monocyclic carbocyclic or heterocyclic group of from 5-7 ring members, or R^A and R^B form a ring when taken together with the nitrogen to which they are attached. In the case where "substituted" means substituted by phenyl, benzyl, phenoxy, or
- 20 benzyloxy, the phenyl ring thereof may itself be substituted with any of the foregoing, except phenyl, benzyl, phenoxy, or benzyloxy.

- As used herein the term "aryl" refers to a mono-, bi- or tri-cyclic carbocyclic aromatic radical, and to two such radicals covalently linked to each other,
- 25 Illustrative of such radicals are phenyl, biphenyl and naphthyl.

- As used herein the unqualified term "carbocyclyl" or "carbocyclic" includes aryl, cycloalkyl and cycloalkenyl and refers to a ring system (monocyclic, bicyclic, tricyclic or bridged) whose ring atoms are all carbon.

30

As used herein the unqualified term "cycloalkyl" refers to a carbocyclic ring system which contains only single bonds between ring carbons.

As used herein the unqualified term "cycloalkenyl" refers to a carbocyclic ring system which contains at least one double bond between a pair of ring carbons.

- 5 As used herein the term "heteroaryl" refers to a mono-, bi- or tri-cyclic aromatic radical containing one or more heteroatoms selected from S, N and O. Illustrative of such radicals are thienyl, benzthienyl, furyl, benzfuryl, pyrrolyl, imidazolyl, benzimidazolyl, thiazolyl, benzthiazolyl, isothiazolyl, benzisothiazolyl, pyrazolyl, oxazolyl, benzoxazolyl, isoxazolyl, benzisoxazolyl, isothiazolyl, triazolyl, benztriazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolyl and indazolyl.

- As used herein the unqualified term "heterocyclyl" or "heterocyclic" includes "heteroaryl" as defined above, and in particular means a mono-, bi- or tri-cyclic or bridged non-aromatic radical containing one or more heteroatoms selected from S, N and O, and to groups consisting of a monocyclic non-aromatic radical containing one or more such heteroatoms which is covalently linked to another such radical or to a monocyclic carbocyclic radical. Illustrative of such radicals are pyrrolyl, furanyl, tetrahydrofuranyl, thienyl, piperidinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, pyrazolyl, pyridinyl, pyrrolidinyl, pyrimidinyl, morpholinyl, piperazinyl, indolyl, morpholinyl, benzfuranyl, pyranyl, tetrahydropyranyl, quinuclidinyl, isoxazolyl, benzimidazolyl, methylenedioxyphenyl, ethylenedioxyphenyl, maleimido and succinimido groups.


- 25 Some compounds of the invention contain one or more chiral centres because of the presence of asymmetric carbon atoms. The presence of asymmetric carbon atoms gives rise to stereoisomers or diastereoisomers with R or S stereochemistry at each chiral centre. The invention includes all such stereoisomers and diastereoisomers and mixtures thereof.

Salts of salt forming compounds of the invention include physiologically acceptable acid addition salts and base salts. Suitable acid addition salts are formed from acids which form non-toxic salts. Examples include the acetate,

aspartate, benzoate, besylate, bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate, citrate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulphate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, saccharate, stearate, succinate, tartrate, tosylate and trifluoroacetate salts. Suitable base salts are formed from bases which form non-toxic salts. Examples include the aluminium, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts.



Methods

Compounds of the invention wherein R_4 represents an amide group $-C(=O)NR_6R_7$ may be prepared by reaction of the appropriate amine HNR_6R_7 with a compound of formula (II) to amidate the carboxylic acid group:





the symbols R_1 , R_3 , X , R_6 and R_7 being as defined in relation to formula (I) above.

Compounds (II) (ie compounds (I) of the invention wherein R_4 is a carboxylic acid group) may be prepared by reaction of a compound of formula (III) with a hydrazine of formula (IV):




This reaction may result in the preparation of a mixture of the position isomers (IIA) and (IIB):



from which the desired isomer (IIA) may be separated.

Compounds (I) wherein R_4 is an ester or amide group may also be prepared from intermediate (III) by reaction with the appropriate hydrazine (IVA)




wherein R_4 is an ester or amide group. Again the reaction may result in a mixture of the ester or amide analogues of the carboxylic acids (IIA) and (IIB), from which the desired ester or amide isomer (I) may be separated.

Alternatively, the carboxylic acid compound (II) may simply be esterified, or amidated.

Compounds (I) wherein R_4 is a "reverse amide" group $-NR_7C(=O)R_6$ may be prepared by Curtius rearrangement (see Ninomiya, K.; Shioiri, T.; Yamada, S.

Tetrahedron (1974), 30(14), 2151-7) of the carboxylic acid (II) to the isocyanate (V)



followed by hydrolysis of the isocyanate group to an amino group and
acylation of the amino group with, for example, the acid chloride Cl-C(=O)R_6 .
In cases where R_7 is not hydrogen, the R_7 substituent may be introduced after
5 the isocyanate reduction step or after the acylation step.

In an alternative route to the "reverse amide" ($\text{R}_4 = -\text{NR}_7\text{C(=O)R}_6$) compounds
of the invention, a compound of structure (V) in which the isocyanate moiety is
replaced by a nitro group may be reduced to the corresponding amine, which
10 may then be acylated to form the desired reverse amide.

Compounds (I) wherein R_4 is a urea group $-\text{NHC(=O)NHR}_6$ or thiourea group
 $-\text{NHC(=S)NHR}_6$ may also be prepared from the isocyanate (V) or the
corresponding isothiocyanate by reaction with the appropriate amine H_2NR_6 .

Compounds (I) wherein R_4 is a carbamate group $-\text{NR}_7\text{C(=O)OR}_6$ may be
prepared by the reaction of the isocyanate with an appropriate alcohol R_6OH .

Further details of the synthetic methods for the preparation of compounds (I)
20 of the invention, and intermediates such as (III), may be found in the
examples herein.

In the compounds of the invention:

The radical $\text{R}_4\text{X-}$ is preferably in the 4-position of the phenyl ring.

X may be, for example a bond, or a $-\text{CH}_2-$ or $-\text{CH}_2\text{CH}_2-$ radical. A bond is
25 presently preferred.

R₃ may be, for example, H, F, Cl, methyl, methoxy, or methylenedioxy.
Currently it is preferred that R₃ is H.

R₁ may be, for example, H, F, Cl, methyl, methoxy, or methylenedioxy.

- 5 Currently it is preferred that R₁ be hydrogen or fluoro, particularly in the 6-position of the 3-oxo-1,3-dihydro-2H-pyrazolo[4,3-c]cinnolin-2-yl ring system.

R₄ represents a carboxylic acid group (-COOH) or an ester thereof, or
-C(=O)NR₆R₇, -NR₇C(=O)R₆, -NR₇C(=O)OR₆ or -NHC(=O)NHR₆, all as
10 defined above.

When R₄ is an ester group, examples include those of formula -COOR
wherein R is methyl, ethyl n- or iso-propyl, n-, sec- or tert-butyl, or
benzyl ester.

15

R₆, when present, represents H, or a radical of formula -(Alk)_m-Q
wherein m, Alk and Q being as defined above. When m is 1, Alk may
be, for example a straight or branched C₁-C₆ alkylene radical, such as
-CH₂-, -CH₂CH₂-, -CH₂CH₂CH₂-, and -CH₂CH(CH₃)CH₂-. Alk may also
20 be, for example, a divalent cyclopropylene, cyclopentylene or
cyclohexylene radical. The radical Alk may be optionally substituted by,
for example, OH, oxo, CF₃, methoxy or ethoxy. The radical Alk may
optionally contain a hetero atom, for example in the form of an ether,
thioether or amino linkage.

25

The group Q may represent, for example, hydrogen; -NR₉R₁₀ wherein
R₉ and R₁₀ may be the same or different and selected from hydrogen,
methyl, ethyl, n- or isopropyl or tert-butyl; an ester group for example a
methyl, ethyl or benzyl ester; or an optionally substituted aryl, aryloxy,
30 cycloalkyl, cycloalkenyl or heterocyclic group, for example phenyl,
phenoxy, cyclopentyl, cyclohexyl, furyl, thienyl, quinuclidinyl, piperidyl,
or piperazinyl group.


R₇ when present represents H or C₁-C₆ alkyl, for example methyl, ethyl n- or iso-propyl, n-, sec- or tert-butyl; or when taken together with the atom or atoms to which they are attached R₆ and R₇ form a monocyclic heterocyclic ring having 5, 6 or 7 ring atoms.

5

Especially preferred are the cases where R₄ represents -C(=O)NR₆R₇ or -NHC(=O)NR₇R₆ wherein R₇ is hydrogen and R₆ represents a radical of formula -(Alk)_m-Q wherein m is 1 and the divalent radical Alk contains 3 or 4 carbon atoms and is unsubstituted, and Q represents -NR₉R₁₀ wherein R₉ and R₁₀ independently represents H; C₁-C₄ alkyl; C₃-C₄ alkenyl; C₃-C₄ alkynyl; C₃-C₆ cycloalkyl; an ester group; an optionally substituted carbocyclic or heterocyclic group; or form a ring when taken together with the nitrogen to which they are attached, which ring is optionally substituted.

10

15 A specific preferred subset of compounds of the invention has formula (IC):



wherein X and R₄ are as specified above. In this subset, the radical R₄X- may be in the 4-position of the phenyl ring. This subset includes in particular, compounds wherein X is a bond and R₄ is -C(=O)NR₆R₇ wherein R₆ and R₇ are as specified above. For example, in such compounds R₆ may be quinuclidinyl and R₇ hydrogen.


20

Specific compounds of the invention include those of the Examples herein.

25


A preferred compound of the invention is 4-(6-fluoro-3-oxo-1,3-dihydro-pyrazolo[4,3-c]cinnolin-2-yl)-N-(2,2-difluoro-ethyl)-benzamide, of formula (A)

14



or a pharmaceutically or veterinarily acceptable salt, hydrate or solvate thereof.

- 5 Another preferred compound of the invention is N-[3-(tert-butyl-methyl-amino)-butyl]-4-(6-fluoro-3-oxo-1,3-dihydro-pyrazolo[4,3-c]cinnolin-2-yl)-benzamide, of formula (B):



- 10 or a pharmaceutically or veterinarily acceptable salt, hydrate or solvate thereof.

- 15 As mentioned above, the invention includes pharmaceutical or veterinary composition comprising a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof together with a pharmaceutically or veterinarily acceptable excipient or carrier. In such compositions, it will be understood that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound

employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the cause and severity of the particular disease undergoing therapy. Optimum dose levels and frequency of dosing will be determined by clinical trial.

5

The compounds with which the invention is concerned may be prepared for administration by any route consistent with their pharmacokinetic properties.

The orally administrable compositions may be in the form of tablets, capsules, powders, granules, lozenges, liquid or gel preparations, such as oral, topical, or sterile parenteral solutions or suspensions. Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinyl-pyrrolidone; fillers for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tableting lubricant, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants for example potato starch, or acceptable wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in normal pharmaceutical practice. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, glucose syrup, gelatin hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.

10

20

25

30

For topical application to the skin, the drug may be made up into a cream, lotion or ointment. Cream or ointment formulations which may be used for the drug are conventional formulations well known in the art, for example as described in standard textbooks of pharmaceuticals such as the British Pharmacopoeia.

For topical application to the eye, the drug may be made up into a solution or suspension in a suitable sterile aqueous or non aqueous vehicle. Additives, for instance buffers such as sodium metabisulphite or disodium edeate; 5 preservatives including bactericidal and fungicidal agents such as phenyl mercuric acetate or nitrate, benzalkonium chloride or chlorhexidine, and thickening agents such as hypromellose may also be included.

The active ingredient may also be administered parenterally in a sterile 10 medium. Depending on the vehicle and concentration used, the drug can either be suspended or dissolved in the vehicle. Advantageously, adjuvants such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle.


15 Embodiments of the invention are described in the following non-limiting Examples:

The following abbreviations are used in the experimental descriptions:

DMF	Dimethyl formamide
DMA	Dimethyl acetamide
DMSO	Dimethyl sulphoxide
HBTU	O-Benzotriazol-1-yl- <i>N,N,N',N'</i> -tetramethyluronium hexafluorophosphate
HPLC	High performance liquid chromatography
LCMS	Liquid chromatography mass spectrum
NMR	Nuclear magnetic resonance spectroscopy

20 Example 1


Step 1: Preparation of (phenylhydrazono)malonic acid:



Sodium mesoxalate monohydrate (5.00 g, 27.8 mmol) was dissolved in 1 M
5 hydrochloric acid (50 ml) to give a colourless cloudy solution. Phenylhydrazine
(3.00 g, 2.72 ml, 27.8 mmol) was added dropwise at room temperature to the
stirred mixture. A yellow precipitate formed, was collected by filtration after 90
min and washed with water (50 ml). The filter cake was triturated with ethyl
acetate / hexane [1:1], filtered and dried under vacuum. The title compound
10 was isolated as a yellow powder (4.74 g, 22.7 mmol, 82%). LCMS: m/z 207
[M-H]⁺.

Alternatively the product can be extracted from the aqueous phase with ethyl
acetate (2 x 250 ml), the organic phase dried over magnesium sulphate,
15 filtered and the solvent removed under vacuum.

Step 2: Preparation of (phenylhydrazono)malonoyl dichloride:




20

(Phenylhydrazono)malonic acid (1.00 g, 4.80 mmol) was mixed under inert
atmosphere with dry chloroform (15 ml) to give a yellow suspension. The
mixture was stirred at room temperature and phosphorus pentachloride (2.19
g, 10.5 mmol) was added portionwise. The reaction mixture was heated to
25 reflux for 1.5 h to give a green solution. The mixture was cooled to room
temperature and diluted with hexane (15 ml). A green precipitate formed, was

collected by filtration and dried under vacuum. The title compound was isolated as a green powder (645 mg, 2.63 mmol, 53%).


Step 3: Preparation of methyl 4-hydroxycinnoline-3-carboxylate



(Phenylhydrazono)malonoyl dichloride (2.45 g, 0.01 mmol) was mixed under inert atmosphere with 1,2-dichloroethane (15 ml) to give a yellow suspension.

Titanium tetrachloride (1.89 g, 1.09 ml) was added dropwise to form a brown solution. The mixture was heated to reflux overnight, cooled to room temperature and quenched dropwise with methanol (15 ml). Stirring was continued for 30 min and volatiles were removed under vacuum. Water (100 ml) was added and the obtained suspension was extracted with *n*-butanol (2 x 50 ml). The combined organic phases were washed with water (2 x 20 ml) and concentrated under vacuum. The title compound was isolated as a green solid (1.04 g, 5.10 mmol, 51%). LCMS: m/z 205 $[M+H]^+$.


Step 4: Preparation of methyl 4-chlorocinnoline-3-carboxylate:



Thionyl chloride (8.15 g, 5 ml) was added dropwise under inert atmosphere to methyl 4-hydroxycinnoline-3-carboxylate (0.50 g, 2.45 mmol). The mixture

was heated to reflux for 1.5 h, cooled to room temperature and excess thionyl chloride was removed under vacuum. Toluene (5 ml) was added to the residue. The mixture was stirred at room temperature overnight. The solids were collected by filtration and dried under vacuum. The title compound was isolated as a brown solid (248 mg, 1.11 mmol, 45%). LCMS: m/z 223 $[M+H]^+$.

Step 5: Preparation of 4-(3-oxo-1,3-dihydro-2H-pyrazolo[4,3-c]cinnolin-2-yl)benzoic acid:



10

4-Hydrazinobenzoic acid (68.4 mg, 0.45 mmol) was mixed at room temperature with ethanol (5 ml) to give a crème-coloured suspension. Methyl 4-chlorocinnoline-3-carboxylate (100 mg, 0.45 mmol) was added and the mixture was heated to 45-50°C for 1 h. The reaction mixture was cooled to room temperature and the solvent was removed under vacuum. Ethyl acetate (10 ml) was added to the residue. The mixture was stirred at room temperature for 1 h. The solids were collected by filtration and dried under vacuum. The title compound was isolated as a brown powder (120 mg, 0.39 mmol, 86%). LCMS: m/z 307 $[M+H]^+$. NMR $[DMSO-d_6]$: δ = 7.69-7.77 (m, 1 H_{aryl}); 7.81-7.90 (m, 2 H_{aryl}); 8.05 (d, J = 8.85, 2 H_{aryl}); 8.20 (d, J = 7.92 Hz, 1 H_{aryl}); 8.33 (d, J = 8.85 Hz, 2 H_{aryl}); 14.64 (s, NH).


20

Alternatively the reaction may be carried out at room temperature. In this case, a longer reaction time of 2-3 h may be required.

25

Example 2

Preparation of *N*-[(dimethylamino)propyl]-4-(3-oxo-1,3-dihydro-2*H*-pyrazolo[4,3-*c*]cinnolin-2-yl)benzamide:



5


4-(3-oxo-1,3-dihydro-2*H*-pyrazolo[4,3-*c*]cinnolin-2-yl)benzoic acid (25 mg, 0.08 mmol) was mixed with DMF (1 ml). Diisopropylethylamine (21 mg, 28 μ l, 0.16 mmol) and 3-dimethylaminopropylamine (8.2 mg, 10.0 μ l, 0.09 mmol) were added followed by HBTU (30.3 mg, 0.08 mmol). The mixture was stirred at room temperature for 2 h. The product was purified by preparative HPLC. The title compound was isolated as a red solid (12.6 mg, 0.032 mmol, 40%). LCMS: m/z 391 $[M+H]^+$.

10

Example 3

Preparation of *N*-benzyl-4-(3-oxo-1,3-dihydro-2*H*-pyrazolo[4,3-*c*]cinnolin-2-yl)benzamide:


15



4-(3-oxo-1,3-dihydro-2*H*-pyrazolo[4,3-*c*]cinnolin-2-yl)benzoic acid (52 mg, 0.17 mmol) was mixed with DMF (2 ml). Diisopropylethylamine (22 mg, 29 μ l, 0.17 mmol) and benzylamine (18.2 mg, 18.6 μ l, 0.17 mmol) were added followed by HBTU (64.5 mg, 0.17 mmol). The mixture was stirred at room temperature for 4 h. The product was purified by preparative HPLC. The title compound was isolated as a red solid (6.6 mg, 0.02 mmol, 10%). LCMS: m/z 396 $[M+H]^+$.


Example 4

Step 1: Preparation of 4-(3-oxo-1,3-dihydro-2*H*-pyrazolo[4,3-*c*]cinnolin-2-yl)benzoyl chloride:



Thionyl chloride (90 ml) was added to 4-(3-oxo-1,3-dihydro-2*H*-pyrazolo-[4,3-*c*]cinnolin-2-yl)benzoic acid (2.36 g, 7.70 mmol). The mixture was heated to reflux for 2 h under nitrogen atmosphere. A dark red solution was obtained, cooled to room temperature and excess thionyl chloride was removed under vacuum. Toluene (30 ml) was added to the residues and the mixture was stirred at room temperature under nitrogen atmosphere until precipitation was complete. The solids were collected by filtration and washed with toluene (2 x 30 ml). The title compound was isolated as a red solid (2.20 g, 6.77 mmol, 88%) LCMS: m/z 321 $[M+H]^+$ (methyl ester resulting from sample make-up in methanol).

Step 2: Preparation of *N*-[(cyclohexylamino)propyl]-4-(3-oxo-1,3-dihydro-2*H*-pyrazolo[4,3-*c*]cinnolin-2-yl)benzamide:




4-(3-oxo-1,3-dihydro-2*H*-pyrazolo[4,3-*c*]cinnolin-2-yl)benzoyl chloride (97 mg, 0.30 mmol) was dissolved in anhydrous DMA (2 ml). Diisopropylethylamine (39 mg, 53 μ l, 0.60 mmol) was added followed by *N*-cyclohexyl-1,3-propanediamine (52 mg, 0.60 mmol). The mixture was stirred for 30 min. Water (5 ml) was added to give a dark red suspension. The mixture was extracted with *n*-butanol (2 x 20 ml). The combined organic phases were washed with water and concentrated under vacuum until precipitation was observed. Hexane (20 ml) and ethyl acetate (10 ml) were added, the solids were collected by filtration and dried under vacuum. The product was isolated as a dark red powder (82 mg, 0.18 mmol, 62%). LCMS: m/z 445 $[M+H]^+$.

10

15

Example 5:

Step 1: Preparation of [(2-Fluorophenyl)hydrazono]malonic acid:




Sodium mesoxalate monohydrate (2.21 g, 12.3 mmol) was dissolved in 1 M hydrochloric acid (50 ml) to give a colourless cloudy solution. 2-Fluorophenylhydrazine hydrochloride (2.00 g, 12.3 mmol) was added portionwise at room temperature to the stirred mixture. A yellow precipitate formed, the mixture was diluted with water (50 ml) and stirring continued overnight. Ethyl acetate (150 ml) was added, the phases were mixed vigorously until the solids had dissolved. The phases were separated and the aqueous phase was washed with ethyl acetate (50 ml). The combined organic phases were dried over magnesium sulfate, filtered and the solvent removed under vacuum. The title compound was isolated as a yellow powder (2.55 g, 11.7 mmol, 92%). LCMS: m/z 227 $[M-H]^+$.

Step 2: Preparation of [(2-Fluorophenyl)hydrazono]malonoyl dichloride:




(2-Fluorophenylhydrazono)malonic acid (1.33 g, 5.88 mmol) was mixed under inert atmosphere with dry chloroform (20 ml) to give a yellow suspension. The mixture was stirred at room temperature and phosphorus pentachloride (2.69 g, 12.9 mmol) was added portionwise. The reaction mixture was heated to reflux for 2 h to give a dark yellow solution. The mixture was cooled to room temperature and concentrated under vacuum until precipitation occurred. The solids were collected by filtration, washed with hexane (30 ml) and dried under vacuum. The title compound was isolated as a yellow powder (760 mg, 2.89 mmol, 49%).

Step 3: Preparation of methyl 8-fluoro-4-hydroxycinnoline-3-carboxylate:



(2-Fluorophenylhydrazono)malonoyl dichloride (19.4 g, 74 mmol) was mixed under inert atmosphere with 1,2-dichloroethane (100 ml) to give a yellow suspension. Titanium tetrachloride (13.9 g, 8.08 ml, 74 mmol) was added dropwise to form a brown solution. The mixture was heated to reflux overnight. Further titanium tetrachloride (13.9 g, 8.08 ml, 74 mmol) was added and heating continued for 24 h. The reaction mixture was cooled to 0-5°C and quenched dropwise with methanol (50 ml). Stirring was continued for 1 h at room temperature and volatiles were removed under vacuum. Water (300 ml) was added and the obtained suspension was extracted with ethyl acetate (3 x 100 ml). The combined organic phases were dried over magnesium sulphate, filtered and concentrated under vacuum. A yellow solid was obtained (12 g crude product). LCMS: m/z 223 $[M+H]^+$.

Step 4: Preparation of 4-(6-fluoro-3-oxo-1,3-dihydro-2*H*-pyrazolo[4,3-*c*]cinnolin-2-yl)benzoic acid:




5

Crude 8-Fluoro-4-hydroxycinnoline-3-carboxylate from the previous stage (1.00 g, 4.95 mmol) was dissolved in thionyl chloride (50 ml). The solution was heated to reflux for 2-3 h until no further gas evolution was observed. The reaction mixture was cooled to room temperature and excess thionyl chloride was removed under vacuum. The crude intermediate was azeotroped with toluene (3 x 25 ml). A dark brown solid was obtained, which was taken up in ethanol (25 ml). 4-Hydrazinobenzoic acid (640 mg, 4.21 mmol) was added and the mixture was stirred at room temperature overnight. The solids were collected by filtration, slurried in 1 M HCl (100 ml), filtered, washed with hexane (50 ml) and dried under vacuum. A brown solid was obtained (890 mg of crude product). LCMS: m/z $[M+H]^+$ 325.

20

Example 6

Step 1: Preparation of 4-(6-fluoro-3-oxo-1,3-dihydro-2*H*-pyrazolo[4,3-*c*]cinnolin-2-yl)benzoic acid chloride:




Crude 4-(6-fluoro-3-oxo-1,3-dihydro-2H-pyrazolo[4,3-c]cinnolin-2-yl)-benzoic acid (1.45 g) from the previous stage was dissolved in thionyl chloride (50 ml).

- 5 The mixture was heated to 70°C for 2-3 h until no further gas evolution was observed. The mixture was cooled to room temperature and excess thionyl chloride was removed under vacuum. The residues were azeotroped with toluene (2 x 20 ml) to give a solid. The solid was collected by filtration, washed with toluene and dried under vacuum. The product was isolated as a
- 10 yellow powder (670 mg, 1.95 mmol). LCMS: m/z [M+H]⁺ 339 (methyl ester resulting from sample make-up in methanol).

Step 2: Preparation of 4-(6-fluoro-3-oxo-1,3-dihydro-2H-pyrazolo[4,3-c]cinnolin-2-yl)-N-(pyrrolidin-1-yl-butyl)benzamide:

15




4-(6-fluoro-3-oxo-1,3-dihydro-2*H*-pyrazolo[4,3-*c*]cinnolin-2-yl)benzoyl chloride (100 mg, 0.29 mmol) was dissolved in anhydrous DMA (2 ml).

Diisopropylethylamine (75 mg, 101 μ l, 0.58 mmol) was added followed by 1-(4-aminobutyl)pyrrolidine (41 mg). The mixture was stirred at room temperature overnight. Water (5 ml) and *n*-butanol (5 ml) were added. The phases were separated. The organic phase was washed with water (2 x 5 ml). The volatiles were removed under vacuum. The product was isolated as a brown powder (50 mg, 0.11 mmol, 37%). LCMS: m/z $[M+H]^+$ 463.

10 Example 7

Preparation of 4-(6-fluoro-3-oxo-1,3-dihydro-2*H*-pyrazolo[4,3-*c*]cinnolin-2-yl)-*N*-(1,2,2,6,6-pentamethylpiperidine-4-yl)benzamide:




4-(6-fluoro-3-oxo-1,3-dihydro-2*H*-pyrazolo[4,3-*c*]cinnolin-2-yl)benzoyl chloride (100 mg, 0.29 mmol) was dissolved in anhydrous DMA (2 ml).

Diisopropylethylamine (75 mg, 101 μ l, 0.58 mmol) was added followed by 4-amino-1,2,2,6,6-pentamethylpiperidine (49 mg, 0.29 mmol). The mixture was stirred overnight. Water (5 ml) and *n*-butanol (5 ml) were added. The phases were separated. The organic phase was washed with water (2 x 5 ml) and the solution was concentrated under vacuum. The title compound was isolated as a dark red solid (50 mg, 0.105 mmol, 36%). LCMS: m/z $[M+H]^+$ 477.

Example 8


Step 1: Preparation of 2-(4-nitrophenyl)-1,2-dihydro-3*H*-pyrazolo [4,3-*c*] cinnolin-3-one



5

Thionyl chloride (326 g, 200 ml) was added dropwise under inert atmosphere to methyl 4-hydroxycinnoline-3-carboxylate (10.0 g, 49 mmol). The mixture was heated to reflux for 2.5 h, cooled to room temperature and excess thionyl chloride was removed under vacuum. Toluene (100 ml) was added to the residue and removed under vacuum. This procedure was repeated with further toluene (100 ml). A brown semi-solid material was obtained and taken up in ethanol (200 ml). 4-Nitrophenylhydrazine (5.99 g, 39.2 mmol) was added portionwise. The mixture was stirred at room temperature overnight. The mixture was heated to 40-45°C for 1 h and cooled to room temperature. The solids were collected by filtration, triturated with ethanol (100 ml) and dried under vacuum. The title compound was isolated as a brown solid (8.42 g, 27.4 mmol, 70%). LCMS: m/z 308 $[M+H]^+$.

Step 2: Preparation of 2-(4-aminophenyl)-1,2-dihydro-3*H*-pyrazolo [4,3-*c*] cinnolin-3-one




20

2-(4-nitrophenyl)-1,2-dihydro-3*H*-pyrazolo [4,3-*c*] cinnolin-3-one (11.4 g, 37.2 mmol) was suspended in a mixture of ethanol (100 ml) and water (100 ml).


5 Iron powder (11.1 g, 200 mmol) and ammonium chloride (5.34 g, 100 mmol) were added. The mixture was heated to 80°C overnight, cooled to room temperature and basified with potassium carbonate to pH 9-10. The solids were removed by filtration through a pad of Celite®. The filtrate was extracted with *n*-butanol (2 x 200 ml). The combined organic phases were concentrated under vacuum to give a dark red solid. The solid was triturated with methanol (100 ml), filtered and dried under vacuum. The title compound was isolated as a dark red powder (5.58g, 20.1 mmol, 57%). LCMS: *m/z* 278 [M+H]⁺.

Step 3: Preparation of *N*-[3-(dimethylamino)propyl]-*N'*-[4-(3-oxo-1,3-dihydro-2*H*-pyrazolo [4,3-*c*]cinnolin-2-yl) phenyl]urea



20 2-(4-aminophenyl)-1,2-dihydro-3*H*-pyrazolo [4,3-*c*] cinnolin-3-one (44 mg, 0.16 mmol) was suspended in toluene under nitrogen atmosphere (0.5 ml) at 0-5°C. DMA (0.5 ml) was added followed by *N,N'*-carbonyldiimidazole (26 mg, 0.16 mmol). The mixture was stirred for 1 h at 0-5°C before mixed with a solution of 3-dimethylaminopropylamine (18 mg, 0.18 mmol) in toluene (0.5 ml). Stirring was continued for 1 h and the product was purified by preparative HPLC. The title compound was isolated as a dark red powder (2.6 mg, 6 μmol, 4%). LCMS: *m/z* 406 [M+H]⁺.

Example 9: Preparation of 4-(3-oxo-1,3-dihydro-2*H*-pyrazolo[4,3-*c*]cinnolin-2-yl)benzoic acid ethyl ester.



- 5 The title compound was prepared by the method of Example 1 step 5, substituting 4-hydrazinobenzoic acid ethyl ester for the parent acid. MS: MH⁺ = 335.2

Results

10

The use of BIAcore biomolecular interaction analysis

Biotinylated human CD80 (hCD80-BT) is a recombinant soluble form of a membrane bound receptor molecule (CD80) which binds to CD28 to initiate T cell activation. The interaction between CD80 and CD28 has been extensively investigated (Collins et al, 2002). Biotinylated human HLA-A2-tax is the recombinant soluble form of a membrane bound receptor molecule that has been used in this example as a control protein, and is not expected to interact with the compounds.

- 20 The BIAcore S51TM system was used for screening the compounds of Examples 1-4 above. A series S sensor chip CM5 was docked onto the BIAcore S51TM. Streptavidin was coupled to the carboxymethyl surface using standard amine coupling. The chip surface was activated with 0.2M EDC / 0.05M NHS, followed by binding of streptavidin (0.25 mg/ml in 10 mM sodium acetate pH 5.0) and saturation of unoccupied sites with 1 M ethylenediamine.
- 25

The BIAcore S51 sensor chip has two separate sensor spots for immobilisation of proteins. hCD80-BT was immobilised on the streptavidin-coated surface of one sensor spot until a response of approximately 3000 RU was observed. A protein to control for non-specific binding of the compound was immobilised on a second sensor spot. The control protein used for these experiments was a biotinylated, soluble form of the human HLA protein.

Dilution series of compounds (1000nM – 0.05nM) were prepared in running buffer (10 mM, pH 7.4, 150 mM NaCl, 0.005% P20; 5% DMSO).

BIAcore S51TM was run at a flow rate of 30 µl/min using running buffer. Compounds and DMSO standard solutions for correction of data for solvent effects were injected. Data were recorded automatically and were analysed using BIAcore S51 Evaluation software.

The interaction between CD80 and the endogenous protein ligand (CD28) is highly specific, but relatively weak, with a K_D of 4750 nM, and an off-rate of greater than 0.2 s^{-1} . The compounds of Examples 2,3,4,6,7 have greater affinity and longer residence times on CD80 than CD28, having K_D s of less than 100nM, and off-rates of 2×10^{-2} , indicating that the cinnolines will be able to compete effectively with the endogenous ligand. The cinnolines showed no detectable interaction with the control protein.

References

Collins AV *et al.* (2002) Immunity 17, 201-210 "The interaction properties of costimulatory molecules revisited"

Inhibition of production of interleukin-2 (IL-2) by human Jurkat T cells.

Method

Human Raji cells were dispensed at a concentration of 2×10^5 cells per well in RPMI-1640 medium supplemented with 10% fetal calf serum, 1%

- penicillin/streptomycin, 1% glutamine (RPMI medium) in a 96-well round bottom microtitre plate. Compounds under investigation (dissolved in 100% DMSO) were diluted to eight-fold the desired final concentration in RPMI medium and added to the required final concentration for a total volume of
- 5 200 μ l per well. After 20 minutes incubation at 37°C, Jurkat T cells were added at a concentration of 2×10^5 cells per well. Monoclonal antibody to CD3 (UCHT1, R&D Systems) was added to the cultures at a final concentration of 1 μ g per ml, and where indicated, monoclonal antibody to CD28 (CD28.2, BD-Pharmingen) was also added at a concentration of 2.5 μ g per ml. Cells were
- 10 cultured at 37°C for 5 hours, after which the plates were centrifuged and the supernatants harvested for IL-2 ELISA assay using the IL-2 Eli-pair kit (DIACLONE Research, Besancon, France) according to the manufacturers instructions.
- 15 By way of example, the compound of Example 2 (AV1142005) gave 65% inhibition at 30 μ M.

Homogenous Time Resolved Fluorescence Assay

- The examples described above were tested in a cell free Homogenous Time
- 20 Resolved Fluorescence (HTRF) assay to determine their activity as inhibitors of the CD80-CD28 interaction.

- In the assay, europium and allophycocyanin (APC) are associated with CD28 and CD80 indirectly (through antibody linkers) to form a complex, which brings
- 25 the europium and APC into close proximity to generate a signal. The complex comprises the following six proteins: fluorescent label 1, linker antibody 1, CD28 fusion protein, CD80 fusion protein, linker antibody 2, and fluorescent label 2. The table below describes these reagents in greater detail.

Fluorescent label 1	Anti-Rabbit IgG labelled with Europium (1 μ g/ml)
Linker antibody 1	Rabbit IgG specific for mouse Fc fragment (3 μ g/ml)
CD28 fusion protein	CD28 - mouse Fc fragment fusion protein (0.48 μ g/ml)

CD80 fusion protein	CD80 mouse Fab fragment (C215) fusion protein (1.9 μ g/ml)
Linker antibody 2	G α M κ -biotin: biotinylated goat IgG specific for mouse kappa chain (2 μ g/ml)
Fluorescent label 2	SA-APC: streptavidin labelled allophycocyanin (8 μ g/ml)

On formation of the complex, europium and APC are brought into proximity and a signal is generated.

- 5 Non-specific interaction was measured by substituting a mouse Fab fragment (C215) for the CD80 mouse Fab fragment fusion protein (1.9 μ g/ml). The assay was carried out in black 384 well plates in a final volume of 30 μ l. Assay buffer: 50mM Tris-HCl, 150mM NaCl pH7.8, containing 0.1% BSA (w/v) added just prior to use.

10

Compounds were added to the above reagents in a concentration series ranging between 100 μ M – 1.7nM. The reaction was incubated for 4 hours at room temperature. Dual measurements were made using a Wallac Victor 1420 Multilabel Counter. First measurement: excitation 340nm, emission 665nm, delay 50 μ s, window time 200 μ s. second measurement: excitation 340nm, emission 615nm, delay 50 μ s, window time 200 μ s. Counts were automatically corrected for fluorescence crossover, quenching and background. The EC50 activities of compounds tested are recorded as:

15

EC50: * = >10 μ M, ** = 1-10 μ M, *** = <1 μ M.

20

The compounds of Examples 1 – 8 had the following activities in the HTRF assay described above:

Example 1 *

Example 2 ***

25

Example 3 ***

Example 4 ***

Example 5 *

Example 6 ***

Example 7 ***

Example 8 ***


Example 9 **

5 Additional Examples















Further examples of compounds of the invention were synthesised by methods analogous to those of Examples 1 – 8 above. The structures of the synthesised compounds are shown in the following Table, together with their activities in the HTRF assay described above.















10













Table




























Example No.	X	W	R	R'	MS MH+	Activity
9a.	H	-	CH ₂ CH ₂ OMe	H	364.2	**
10.	H	-		H	446.2	***
11.	H	-	CH ₂ CH ₂ NMe ₂	H	377.1	***
12.	H	-		H	419.1	***
13.	H	-		H	433.1	***
14.	H	-		H	442.0	*
15.	H	-	Ph	H	382.0	**














16.	H	-		H	463.0	*
17.	H	-		H	448.8	**
18.	H	-		H	403.1	***
19.	H	-		H	410.0	*
20.	H	-		H	411.0	***
21.	H	-		H	441.2	**
22.	H	-		H	431.1	**
23.	H	-		H	414.1	***
24.	H	-		H	402.2	**
25.	H	-		H	418.4	*
26.	H	-		H	418.2	***
27.	H	-		H	418.2	*
28.	H	-		H	417.9	**
29.	H	-		H	378.0	***














30.	H	-		H	445.2	***
31.	H	-		H	479.0	**
32.	H	-		H	445.2	***
33.	H	-		H	376.2	**
34.	H	-		H	420.0	**
35.	H	-		H	400.0	**
36.	H	-		H	418.0	*
37.	H	-		H	508.1	***
38.	H	-		H	444.2	*
39.	H	-		H	441.1	**
40.	H	-		H	467.2	**
41.	H	-		H	424.1	**
42.	H	-		H	496.9	**
43.	H	-		H	404.1	**











44.	H	-		H	480.0	*
45.	H	-		H	421.8	**
46.	H	-	Et	H	334.2	***
47.	H	-		H	425.0	***
48.	H	-	CH ₂ CH ₂ NHMe	H	363.0	***
49.	H	-	CH ₂ CH ₂ NHEt	H	377.1	***
50.	H	-		H	394.2	**
51.	H	-	CH ₂ CH ₂ OH	H	350.2	***
52.	H	-	CH ₂ CH ₂ CH ₂ NHMe	H	377.2	***
53.	H	-	CH ₂ CH ₂ CH ₂ OiPr	H	406.2	***
54.	H	-	CH ₂ CH ₂ CH ₂ CH ₂ NH ₂	H	377.2	***
55.	H	-		H	390.2	***
56.	H	-		H	414.1	**
57.	H	-		H	388.2	**
58.	H	-	CH ₂ CH ₂ CH ₂ N(nBu) ₂	H	475.2	***
59.	H	-	cyclododecyl	H	472.2	*
60.	H	-	CH ₂ CH ₂ NEt ₂	H	405.1	***
61.	H	-		H	417.2	***
62.	H	-		H	402.2	**
63.	H	-	CH ₂ CH ₂ OPh	H	426.0	**
64.	H	-		H	480.2	**
65.	H	-		H	475.2	**
66.	H	-		H	406.1	**















67.	H	-	$\text{CH}_2\text{CH}_2\text{CH}_2\text{OnBu}$	H	420.0	***
68.	H	-		H	459.3	***
69.	H	-		H	417.3	***
70.	H	-	 (R isomer)	H	362.3	***
71.	H	-	 (S isomer)	H	362.3	***
72.	H	-	$\text{CH}(\text{Et})_2$	H	376.3	**
73.	H	-	$\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{Ph}$	H	438.4	**
74.	H	-		H	492.2	**
75.	H	-		H	416.3	**
76.	H	-		H	411.2	**
77.	H	-	$\text{CH}_2\text{CH}_2\text{SEt}$	H	394.2	***
78.	H	-	Cyclopropyl	H	346.2	**
79.	H	-		H	417.3	***
80.	H	-		H	479.3	***
81.	H	-		H	447.2	***
82.	H	-	$\text{CH}_2\text{CH}_2\text{CH}(\text{CH}_3)\text{CH}_3$	H	376.2	**
83.	H	-	cyclopentyl	H	374.2	**
84.	H	-	nPropyl	H	348.2	**
85.	H	-	$\text{CH}_2\text{CH}_2\text{tBu}$	H	390.3	**
86.	H	-		H	479.3	***
87.	H	-	$\text{CH}_2\text{cycloheptyl}$	H	416.4	*














88.	H	-		H	390.3	**
89.	H	-		H	376.3	***
90.	H	-		H	480.2	**
91.	H	-		H	477.1	***
92.	H	-		H	432.4	*
93.	H	-		H	420.1	**
94.	H	-		H	465.3	***
95.	H	-		H	411.4	***
96.	H	-		H	404.3	**
97.	H	-		H	463.0	**
98.	H	-		H	465.4	**
99.	H	-		H	434.4	**
100.	H	-		H	400.3	*
101.	H	-		H	518.4	***













102.	H	-		H	418.4	**
103.	H	-		H	445.4	***
104.	H	-		H	461.4	**
105.	H	-		H	438.4	*
106.	H	-		H	394.3	**
107.	H	-		H	376.3	**
108.	H	-		H	391.4	***
109.	H	-		H	393.4	***
110.	H	-		H	405.5	***
111.	H	-	CH ₂ CH ₂ CH ₂ OH	H	364.4	**
112.	H	-	CH ₂ CH ₂ CH ₂ CH ₂ CH ₂ OH	H	392.4	***
113.	H	-	nHexyl	H	390.4	**
114.	H	-		H	489.4	**
115.	H	-		H	378.4	**
116.	H	-		H	406.4	*
117.	H	-		H	505.5	**















118.	H	-		H	406.4	**
119.	H	-		H	378.4	**
120.	H	-		H	416.4	**
121.	H	-		H	442.4	**
122.	H	-		H	442.4	*
123.	H	NH		H	494.3	**
124.	H	NH		H	405.3	*
125.	H	NH		H	432.3	**
126.	H	NH		H	429.3	*
127.	H	NH		H	403.3	*
128.	H	NH	CH ₂ CH ₂ CH ₂ OEt	H	407.2	**
129.	H	NH		H	461.3	***
130.	H	NH	CH ₂ CH ₂ NMe ₂	H	392.2	***
131.	H	NH	allyl	H	361.3	***
132.	H	NH		H	434.3	***
133.	H	NH	CH ₂ CH ₂ CH ₂ OMe	H	393.2	**
134.	H	NH		H	460.3	***













135.	H	NH		H	474.3	**
136.	H	NH		H	420.1	*
137.	H	NH		H	449.2	**
138.	H	NH		H	377.3	**
139.	H	NH	iPr	H	363.3	**
140.	H	NH	CH ₂ CH ₂ OMe	H	379.3	**
141.	H	NH	CH ₂ CH ₂ NHiPr	H	406.2	***
142.	H	NH	CH ₂ CH ₂ NHMe	H	378.2	***
143.	H	NH	CH ₂ CH ₂ NHEt	H	392.2	***
144.	H	NH	CH ₂ CH ₂ NHnPr	H	406.2	***
145.	H	NH	CH ₂ CH ₂ OCH ₂ CH ₂ OH	H	409.2	***
146.	H	NH	CH ₂ CH ₂ OH	H	365.2	***
147.	H	NH	CH ₂ CH ₂ Ph	H	425.3	**
148.	H	NH	CH ₂ CH ₂ CH ₂ NHiPr	H	420.2	***
149.	H	NH	CH ₂ CH ₂ CH ₂ OiPr	H	421.2	**
150.	H	NH	CH ₂ CH ₂ CH ₂ OH	H	379.2	***
151.	H	NH	CH ₂ CH ₂ CH ₂ CH ₂ CH ₂ OH	H	407.2	**
152.	H	NH		H	490.1	*
153.	H	NH		H	405.3	**
154.	H	NH		H	393.1	**
155.	H	NH		H	470.3	**
156.	H	NH		H	421.2	**
157.	H	NH		H	378.1	**













158.	H	NH		H	421.1	**
159.	H	NH	$\text{CH}_2\text{CH}_2\text{CH}_2\text{OC}_{12}\text{H}_{25}$	H	547.3	***
160.	H	NH	$\text{CH}_2\text{CH}_2\text{CH}_2\text{OnBu}$	H	435.2	*
161.	H	NH	$\text{CH}_2\text{CH}_2\text{CH}_2\text{SMe}$	H	409.2	**
162.	H	NH		H	432.3	***
163.	H	NH		H	519.9	**
164.	H	NH		H	461.2	*
165.	H	NH		H	375.2	**
166.	H	NH		H	405.2	**
167.	H	NH		H	377.3	**
168.	H	NH		H	462.4	***
169.	H	NH		H	430.3	***
170.	H	NH	$\text{CH}_2\text{CH}_2\text{CHO}$	H	377.2	*
171.	H	NH		H	393.3	***
172.	H	NH		H	494.3	**
173.	H	NH		H	391.3	**
174.	H	NH		H	393.2	***
175.	H	NH		H	435.2	***
176.	H	-	$\text{CH}_2\text{CH}_2\text{CH}_2\text{NEt}_2$	H	419.4	***













177.	H	NH	nBu	H	377.4	**
178.	H	NH	CH ₂ CH ₂ SMe	H	395.3	**
179.	H	NH		H	448.4	***
180.	H	NH		H	523.3	*
181.	H	NH		H	419.4	*
182.	H	NH		H	464.3	**
183.	H	NH		H	418.4	***
184.	H	NH		H	426.3	**
185.	H	NH		H	434.4	***
186.	H	NH		H	460.4	***
187.	H	NH	CH(Et) ₂	H	391.4	**
188.	H	NH	CH ₂ CH ₂ CH ₂ CH ₂ Ph	H	453.4	*
189.	H	NH		H	507.5	**
190.	H	NH		H	419.4	**
191.	H	NH		H	406.4	??
192.	H	NH		H	435.4	*
193.	H	NH		H	454.5	***










194.	H	NH		H	431.5	*
195.	H	NH		H	405.4	**
196.	H	NH		H	426.4	***
197.	H	NH		H	494.5	**
198.	H	NH		H	405.4	**
199.	H	NH		H	415.5	*
200.	H	NH	CH ₂ CH ₂ SCH ₂ Ph	H	471.4	*
201.	H	NH		H	457.5	*
202.	H	NH		H	457.4	*
203.	H	NH		H	391.4	*
204.	H	NH	CH ₂ cycloheptyl	H	431.5	*
205.	H	NH		H	435.4	*
206.	H	NH	CH ₂ CH ₂ N(nBu) ₂	H	476.5	***
207.	H	NH		H	405.4	**
208.	H	NH	CH ₂ CH ₂ OPh	H	441.4	**
209.	H	NH		H	433.4	*












210.	H	NH		H	393.4	***
211.	H	NH		H	495.5	*
212.	H	NH		H	509.4	*
213.	H	NH		H	478.5	***
214.	H	NH		H	480.4	***
215.	H	NH		H	435.4	*
216.	H	NH		H	449.4	*
217.	H	NH		H	426.4	**
218.	H	NH		H	419.5	*
219.	H	NH		H	540.5	**
220.	H	NH		H	492.5	*
221.	H	NH		H	405.5	*
222.	H	NH		H	434.4	***
223.	H	NH		H	449.4	**










224.	H	NH		H	522.5	***
225.	H	NH		H	471.4	*
226.	H	NH		H	437.4	*
227.	H	NH		H	576.4	*
228.	H	NH		H	446.4	***
229.	H	NH		H	432.4	***
230.	H	NH		H	383.3	*
231.	H	NH		H	429.4	***
232.	6-F	-	CH ₂ CH ₂ CH ₂ NMe ₂	H	409.4	***
233.	6-F	-		H	449.4	***
234.	6-F	-		H	477.4	***
235.	6-F	-		H	463.4	***
236.	H	-		H	456.4	*











237.	H	-		H	439.4	***
238.	H	-		H	390.3	**
239.	H	-	cycloButyl	H	360.4	**
240.	H	-		H	426.4	***
241.	H	-	nButyl	H	362.4	**
242.	H	-		H	386.4	***
243.	H	-	iPr	H	348.4	***
244.	H	-		H	402.4	**
245.	H	-	nHeptyl	H	404.4	**
246.	H	-	Allyl	H	346.3	***
247.	H	-	CH ₂ CH ₂ CH ₂ OMe	H	378.4	***
248.	H	-		H	464.3	*
249.	H	-		H	464.3	*
250.	H	-		H	414.3	***
251.	H	-	nPentyl	H	376.4	*
252.	H	-		H	422.3	*
253.	H	-		H	442.3	*
254.	H	-		H	508.2	*
255.	H	-		H	416.3	*












256.	H	-		H	403.4	**
257.	H	-		H	456.4	*
258.	H	-		H	362.3	***
259.	H	-		H		***
260.	H	-		H		**
261.	H	NH		H	431.5	*
262.	H	NH		H	405.4	*
263.	H	NH		H	391.4	**
264.	H	NH		H	518.5	*
265.	H	NH		H		*
266.	H	-		H	511.4	***
267.	H	-		H	391.4	***












268.	H	-		H	449.4	**
269.	H	-	CH ₂ CH ₂ NHnPr	H	391.4	***
270.	H	-	CH ₂ CH ₂ Ph	H	410.4	*
271.	H	-	CH ₂ CH ₂ CH ₂ CH ₂ CH ₂ CH ₂ NH ₂	H	405.4	***
272.	H	-		H	414.4	*
273.	H	-	CH ₂ CH ₂ CH ₂ OC ₁₂ H ₂₅	H	532.6	*
274.	H	-	CH ₂ CH ₂ CH ₂ SCH ₃	H	394.4	***
275.	H	-		H	446.4	**
276.	H	-	CH(Et)CH ₂ OCH ₂ Ph	H	468.4	**
277.	H	-		H	390.3	**
278.	H	-		H	415.4	***
279.	H	-	CH ₂ CH ₂ NHnBu	H	405.4	***
280.	H	-	CH ₂ CH ₂ NHCH ₂ CH ₂ NEt ₂	H	448.5	***
281.	H	-	CH ₂ CH ₂ NHCH ₂ Ph	H	439.4	***
282.	H	NH	Et	H	349.4	***
283.	H	NH		H	457.4	*
284.	H	NH		H	429.3	*
285.	H	NH		H	415.3	***
286.	H	NH		H	455.3	*










287.	H	NH		H	433.4	***
288.	H	NH		H	522.5	***
289.	H	NH		H	431.3	**
290.	H	NH		H	418.4	***
291.	H	NH	$\text{CH}_2\text{CH}_2\text{CH}_2\text{Ph}$	H	439.4	*
292.	H	NH		H	495.4	*
293.	H	NH		H	454.3	*
294.	H	NH		H	533.5	**
295.	H	NH	$\text{CH}_2\text{CH}_2\text{CH}_2\text{NHCH}_3$	H	392.4	***
296.	H	NH		H	456.4	*
297.	H	NH		H	446.4	**
298.	H	NH		H	429.4	***
299.	H	NH		H	417.5	*











300.	H	NH		H	433.5	***
301.	H	NH		H	460.5	***
302.	H	NH		H	486.4	*
303.	H	NH		H	476.4	*
304.	H	NH	CH(CH ₃)CH ₂ CH ₂ Ph	H	453.4	*
305.	H	NH		H	433.5	*
306.	H	NH	CH ₂ CH(OMe) ₂	H	409.4	***
307.	H	NH	CH ₂ CH(OEt) ₂	H	437.5	**
308.	H	NH	CH ₂ CH(CH ₃)CH ₂ CH ₃	H	391.4	**
309.	H	NH	CH(CH ₃)CH ₂ CH ₃	H	377.4	**
310.	H	NH		H	432.4	***
311.	H	-	CH ₂ CHF ₂	H	370.4	***
312.	H	-	CH ₂ CH ₂ CF ₃	H	402.4	***
313.	H	-		H	440.5	**
314.	H	-		H	412.5	***
315.	H	-		H	422.5	***












316.	H	-		H	402.5	**
317.	H	-		H	416.5	**
318.	H	-		H	442.5	***
319.	H	-	<i>t</i> Bu	H	362.5	***
320.	H	-	CH ₂ Si(CH ₃) ₃	H	392.5	*
321.	H	-	CH(CH ₃)CH ₂ CH ₂ CH ₃	H	376.5	***
322.	H	-	CH(CH ₃)CH ₂ CH ₂ CH ₂ CH ₃	H	390.5	***
323.	6-F	-		H	497.6	***
324.	6-F	NH	CH ₂ CH ₂ N(CH ₃) ₂	H	410.5	***
325.	8-F	-		H	449.3	***
326.	8-F	-	CH ₂ CH ₂ N(Et) ₂	H	423.3	***
327.	8-F	-		H	435.3	***
328.	8-F	-		H	497.3	***
329.	8-F	-	CH ₂ CH ₂ CH ₂ N(Bu) ₂	H	493.4	***
330.	8-F	-	CH ₂ CH ₂ CH ₂ N(Et) ₂	H	437.3	***
331.	8-F	-		H	435.5	***
332.	8-F	-		H	463.3	***
333.	6-F	-	CH ₂ CH=CHCH ₃	H	378.2	***
334.	6-F	-		H	525.3	***











335.	6-F	-		H	479.3	***
336.	6-F	-		H	517.4	***
337.	6-F	-		H	511.3	***
338.	H	-		H	447.3	***
339.	H	-		H	445.3	***
340.	6-F	-		H	378.2	***
341.	6-F	-	CH ₂ CH ₂ NHnPr	H	409.3	***
342.	6-F	-	CH ₂ CH ₂ N(Et) ₂	H	423.3	***
343.	6-F	-		H	435.3	***
344.	6-F	-	CH ₂ CH ₂ NHnBu	H	423.3	***
345.	6-F	-	CH ₂ CH ₂ CH ₂ N(nBu) ₂	H	493.4	***
346.	6-F	-	CH ₂ CH ₂ CH ₂ N(Et) ₂	H	437.3	***
347.	6-F	-	CH ₂ CH ₂ NHCH ₂ Ph	H	457.3	***
348.	6-F	-	CH ₂ CH ₂ CH ₂ NHiPr	H	423.3	***
349.	6-F	-		H	421.3	***
350.	6-F	-		H	451.3	***
351.	6-F	-	CH ₂ CH ₂ CH ₂ CH ₂ NH ₂	H	395.3	***
352.	6-F	-		H	435.3	***
353.	6-F	-		H	433.3	***
354.	6-F	-	CH ₂ CH ₂ CH ₂ OnBu	H	438.3	***
355.	6-F	-	CH ₂ CH ₂ CH ₂ NHMe	H	395.3	***










356.	6-F	-	$\text{CH}_2\text{CH}_2\text{NHMe}$	H	381.3	***
357.	6-F	-	$\text{CH}_2\text{CH}_2\text{NHEt}$	H	395.3	***
358.	6-F	-		H	463.4	***
359.	6-F	-		H	481.3	***
360.	6-F	-		H	462.2	**
361.	6-F	-		H	488.3	***
362.	6-F	-		H	442.3	**
363.	6-F	-		H	462.2	**
364.	6-F	-		H	462.2	**
365.	6-F	-		H	506.2, 508.2	*
366.	6-F	-		H	442.3	**
367.	6-F	-		H	442.3	**
368.	6-F	-		H	506.2, 508.2	**











369.	6-F	-		H	480.2	**
370.	6-F	-		H	496.2	**
371.	6-F	-		H	496.2	**
372.	6-F	-		H	496.2	**
373.	6-F	-		H	446.3	**
374.	6-F	-		H	463.3	***
375.	6-F	-	tBu	H	380.3	***
376.	6-F	-	CH ₂ CHF ₂	H	388.2	***
377.	6-F	-	CH ₂ CH=CH ₂	H	364.2	***
378.	6-F	-		H	553.4	***
379.	6-F	-		H	524.4	**
380.	6-F	-		H	575.3	***
381.	8-F	-	CH ₂ CH ₂ CH ₂ N(Me) ₂	H	409.3	***












382.	8-F	-		H	463.3	***
383.	8-F	-	CH ₂ CH ₂ NHEt	H	409.3	***
384.	8-F	-	CH ₂ CH ₂ NHBu	H	423.3	***
385.	8-F	-	CH ₂ CH ₂ CH ₂ NHiPr	H	423.3	***
386.	8-F	-	CH ₂ CH ₂ CH ₂ CH ₂ OH	H	396.3	***
387.	9-F	-	CH ₂ CH ₂ CH ₂ N(Me) ₂	H	409.2	***
388.	9-F	-		H	449.2	***
389.	9-F	-		H	463.3	***
390.	9-F	-		H	477.3	***
391.	9-F	-		H	421.2	***
392.	9-F	-	CH ₂ CH ₂ CH ₂ N(Et) ₂	H	437.2	***
393.	9-F	-		H	435.2	***
394.	9-F	-		H	463.2	***
395.	9-F	-	CH ₂ CH ₂ CH ₂ NHiPr	H	423.2	***
396.	9-F	-	CH ₂ CH ₂ CH ₂ NHMe	H	395.2	***
397.	9-F	-		H	451.2	***
398.	9-F	-	CH ₂ CH ₂ CH ₂ N(nBu) ₂	H	493.3	***
399.	9-F	-		H	483.2	***
400.	9-F	-	tBu	H	380.2	***
401.	9-F	-		H	433.2	***

402.	9-F	-			475.2	**
403.	9-F	-		H	463.3	***
404.	9-F	-		H	437.2	***
405.	9-F	-		H	421.2	***
406.	8-Me	-	$\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{Me})_2$	H	405.3	***
407.	8-Me	-		H	459.3	***
408.	8-Me	-		H	473.4	***
409.	8-Me	-		H	445.3	***
410.	6-F	-		H	421.3	***
411.	6-Cl	-	$\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{Me})_2$	H	425.3	***
412.	6-Cl	-		H	479.2	***
413.	6-Cl	-		H	465.3	***
414.	6,8-diF	-	$\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{Me})_2$	H	427.3	***
415.	6,8-diF	-		H	481.3	***












416.	6,8-diF	-		H	467.2	***
417.	6-F	-		H		***
418.	8-MeO	-	CH ₂ CH ₂ CH ₂ NHMe	H	407.2	***
419.	6-F	-		H	481.2	***
420.	6-F	-		H	437.2	***
421.	6-F	-			475.2	**
422.	6-F	-	CH ₂ CF ₂ CF ₂ CF ₃	H	456.1	***
423.	6-F	-	CH ₂ CH ₂ CF ₃	H	420.1	***
424.	6-F	-		H	378.1	***
425.	6-F	-		H	392.2	***
426.	6-F	-	CH ₂ CH ₂ F	H	370.1	***
427.	8-F	-		H	477.3	***
428.	6,9-diF	-	CH ₂ CH ₂ CH ₂ NHMe	H	413.2	***
429.	6,9-diF	-		H	481.3	***
430.	6,9-diF	-		H	467.2	***










431.	6,9-diF	-		H	495.3	***
432.	6-F	-	$\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{Et})\text{Me}$	H	437.2	***
433.	6-F	-	$\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{Et})_2$	H	451.3	***
434.	6-F	-		H	465.2	***
435.	6-F	-	$\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{Me})\text{CH}_2\text{CH}=\text{CH}_2$	H	449.2	***
436.	6-F	-		H	491.4	***
437.	6-F	-	$\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{F}$	H	398.2	***
438.	6-F	-		H	471.2	**
439.	6-F	-		H	463.3	***
440.	6-F	-		H	407.2	***
441.	6-F	-		H	409.3	***
442.	6-F	-	$\text{CH}_2\text{CH}_2\text{CH}_2\text{NHnPr}$	H	423.2	***
443.	6-F	-		H	409.2	***
444.	6-F	-		H	421.1	***
445.	6-F	-	$\text{CH}_2\text{CH}_2\text{CH}_2\text{NH}_2$	H	381.2	***
446.	8-Cl	-	$\text{CH}_2\text{CH}_2\text{CH}_2\text{N}(\text{Me})_2$	H	425.2	***

447.	8-Cl	-		H	493.2	***
448.	8-Cl	-		H	479.3	***
449.	8-Cl	-		H	465.2	***
450.	6-F	-	Et	H	352.2	***
451.	6-F	-		H	463.3	***
452.	6-F	-	Et	nPr	394.2	**
453.	6-F	-		H	435.2	***
454.	6-F	-		H	477.3	***
455.	6-F	-	CH ₂ tBu	H	394.2	***
456.	6-F	-		H	503.3	***
457.	6-F	-		H	539.3	***
458.	6-F	-		H	471.2	***
459.	6-F	-	CH ₂ CH ₂ CH ₂ CH ₂ N(CH ₂ CH=CH ₂) ₂	H	475.3	***
460.	6-F	-		H	493.3	***

461.	6-F	-			422.2	***
462.	6-F	-		H	477.3	***
463.	6-F	-			406.2	***
464.	6-F	-		H	477.3	***
465.	6-F	-			406.2	***
466.	6-F	-		H	519.2	***
467.	6-F	-	CH ₂ CF ₂ CF ₂ H	H	438.1	***
468.	6-F	-		H	491.3	***
469.	6-F	-		H	503.3	***
470.	6-F	-		H	531.3	***
471.	6-F	-		H	481.2	***
472.	6-F	-		H	449.3	***
473.	8-F	-	CH ₂ CF ₂ H	H	388.1	***
474.	6-F	-	allyl	allyl	404.2	**
475.	6-F	-	CH ₂ CH ₂ CF=CF ₂	H	432.1	**

476.	6-F	-		H	507.3	***
477.	6-F	-		H	491.3	***
478.	6-F	-		H	465.3	***
479.	6-F	-		H	451.2	***
480.	6-F	-		H	465.2	***
481.	6-F	-		H	465.2	***
482.	6-F	-		H	363.1	***
483.	6-F	-		H	461.3	***
484.	6-F	-		H	515.3	***
485.	6-F	-		H	416.2	***
486.	6-F	-		H	377.1	***
487.	6-F	-	$C(CH_2OH)_3$	H	428.2	***
488.	6-F	-		H	393.1	***
489.	6-F	-			421.2	***

490.	6-F	-			407.1	***
491.	6-F	-	CH ₂ CONH ₂	H	381.2	***
492.	6-F	-		H	454.1	***
493.	6-F	-		H	398.1	***
494.	6-F	-			420.2	**
495.	6-F	-			446.2	
496.	6-F	-			446.2	
497.	6-F	-		H	439.1	**
498.	6-F	-		H	419.2	***
499.	6-F	-		H	421.2	***
500.	6,9-diF	-	CH ₂ CHF ₂	H	406.2	***
501.	6-F	-		H	422.2	***
502.	6-F	-		H	396.2	***

503.	6-F	-		H	450.2	**
504.	6-F	-		H	436.2	**
505.	6-F	-	$\text{CH}_2\text{CH}_2\text{NHCH}_2\text{CH}_2\text{OH}$	H	411.2	***
506.	6-F	-		H	464.2	**
507.	6-F	-	$\text{CH}(\text{CH}_2\text{OH})_2$	H	398.1	***
508.	6-F	-	$\text{CH}(\text{CH}_3)\text{CH}_2\text{OH}$	H	382.1	***
509.	6-F	-	$\text{CH}(\text{CH}_2\text{CH}_3)\text{CH}_2\text{OH}$	H	396.2	***
510.	6-F	-		H	456.2	**
511.	6-F	-		H	474.1	**
512.	6-F	-		H	520.2	*
513.	6-F	-		H	474.1	**
514.	6-F	-		H	458.2	***
515.	6-F	-		H	497.2	**
516.	6-F	-	$\text{C}(\text{CH}_3)_2\text{CH}_2\text{OH}$	H	396.2	*

517.	6-F	-	C CH ₃ (CH ₂ OH) ₂	H	412.1	***
------	-----	---	---	---	-------	-----


Examples of the result of testing the above compounds in the assay for inhibition of production of interleukin-2 (IL-2) by human Jurkat T cells,

5 described above, are as follows:

Example No (see table)	Compound Concentration (μM)	Percentage Inhibition (relative to DMSO = 0%)
478	10	56.0
376	10	56.7
353	10	77.4
429	10	58.8
349	10	79.5
68	10	71.7
235	10	59.3
288	30	72
162	30	54.4
350	10	74.2
381	10	48.5
442	10	58.9
482	10	39.2
472	10	58.4
453	10	55.7
53	30	63.8

Claims:

1. A compound of formula (I) or a pharmaceutically or veterinarily acceptable salt, hydrate or solvate thereof:



wherein

R_1 and R_3 independently represent H; F; Cl; Br; $-\text{NO}_2$; $-\text{CN}$; $\text{C}_1\text{-C}_6$ alkyl optionally substituted by F or Cl; or $\text{C}_1\text{-C}_6$ alkoxy optionally substituted by F;

R_4 represents a carboxylic acid group ($-\text{COOH}$) or an ester thereof, or $-\text{C}(=\text{O})\text{NR}_6\text{R}_7$, $-\text{NR}_7\text{C}(=\text{O})\text{R}_6$, $-\text{NR}_7\text{C}(=\text{O})\text{OR}_6$, $-\text{NHC}(=\text{O})\text{NR}_7\text{R}_6$ or $-\text{NHC}(=\text{S})\text{NR}_7\text{R}_6$ wherein

R_6 represents H, or a radical of formula $-(\text{Alk})_m\text{-Q}$ wherein

m is 0 or 1

Alk is an optionally substituted divalent straight or branched $\text{C}_1\text{-C}_{12}$ alkylene, or $\text{C}_2\text{-C}_{12}$ alkenylene, or $\text{C}_2\text{-C}_{12}$ alkynylene radical or a divalent $\text{C}_3\text{-C}_{12}$ carbocyclic radical, any of which radicals may contain one or more $-\text{O}-$, $-\text{S}-$ or $-\text{N}(\text{R}_8)-$ links wherein R_8 represents H or $\text{C}_1\text{-C}_4$ alkyl, $\text{C}_3\text{-C}_4$ alkenyl, $\text{C}_3\text{-C}_4$ alkynyl, or $\text{C}_3\text{-C}_6$ cycloalkyl, and

Q represents H; $-\text{NR}_9\text{R}_{10}$ wherein R_9 and R_{10} independently represents H; $\text{C}_1\text{-C}_4$ alkyl; $\text{C}_3\text{-C}_4$ alkenyl; $\text{C}_3\text{-C}_4$ alkynyl; $\text{C}_3\text{-C}_6$ cycloalkyl; an ester group; an optionally substituted carbocyclic or heterocyclic group; or R_9 and R_{10} form a ring when taken

together with the nitrogen to which they are attached, which ring is optionally substituted; and

5 R_7 represents H or C_1 - C_6 alkyl; or when taken together with the atom or atoms to which they are attached R_6 and R_7 form an optionally substituted monocyclic heterocyclic ring having 5, 6 or 7 ring atoms; and

10 X represents a bond or a divalent radical of formula $-(Z)_n-(Alk)-$ or $-(Alk)-(Z)_n-$ wherein Z represents $-O-$, $-S-$ or $-NH-$, Alk is as defined in relation to R_6 and n is 0 or 1.

2. A compound as claimed in claim 1 wherein the radical R_4X- is in the 4-position of the phenyl ring.

15

3. A compound as claimed in claim 1 or claim 2 wherein X is a bond.

4. A compound as claimed in any of the preceding claims wherein R_3 is hydrogen.

20

5. A compound as claimed in any of the preceding claims wherein R_1 is hydrogen or fluoro.

6. A compound as claimed in any of the preceding claims wherein R_4 represents $-C(=O)NR_6R_7$ wherein R_6 and R_7 are as defined in claim 1.

25

7. A compound as claimed in any of the preceding claims wherein R_4 represents $-NHC(=O)NR_7R_6$ wherein R_6 and R_7 are as defined in claim 1.

30

8. A compound as claimed in claim 7 wherein R_6 is a quinuclidinyl radical.

9. A compound as claimed in any of the preceding claims wherein R_6 represents a radical of formula $-(Alk)_m-Q$ wherein m is 1 and the divalent radical Alk contains 3 or 4 carbon atoms and is unsubstituted, and Q

represents $-NR_9R_{10}$ wherein R_9 and R_{10} independently represent H; C_1-C_4 alkyl; C_3-C_4 alkenyl; C_3-C_4 alkynyl; C_3-C_6 cycloalkyl; an ester group; an optionally substituted carbocyclic or heterocyclic group; or form a ring when taken together with the nitrogen to which they are attached, which ring is optionally substituted.

10. A compound as claimed in any of claims 6 to 8 wherein R_7 is hydrogen.

11. A compound as claimed in claim 1 wherein Q represents H; $-CF_3$; $-OH$; $-SH$; $-NR_8R_8$ wherein each R_8 independently represents H; C_1-C_4 alkyl; C_3-C_4 alkenyl; C_3-C_4 alkynyl; C_3-C_6 cycloalkyl; an ester group; an optionally substituted aryl, aryloxy, cycloalkyl, cycloalkenyl or heterocyclic group; or form a ring when taken together with the nitrogen to which they are attached; and

R_7 represents H or C_1-C_6 alkyl; or when taken together with the atom or atoms to which they are attached R_6 and R_7 form a monocyclic heterocyclic ring having 5, 6 or 7 ring atoms.

12. A compound as claimed in claim 11 wherein R_4 represents a carboxylic acid group ($-COOH$) or an ester group of formula $-COOR$ wherein R is methyl, ethyl, n- or iso-propyl, n-, sec- or tert-butyl or benzyl.

13. A compound as claimed in claim 11 or claim 12 wherein R_6 represents a radical of formula $-(Alk)_m-Q$ wherein m is 1, Alk is $-CH_2-$, $-CH_2CH_2-$, $-CH_2CH_2CH_2-$, or $-CH_2CH(CH_3)CH_2-$, or a divalent cyclopropylene, cyclopentylene or cyclohexylene radical, optionally substituted by OH, oxo, CF_3 , methoxy or ethoxy, and Q represents hydrogen; $-NR_8R_8$ wherein each R_8 may be the same or different and selected from hydrogen, methyl, ethyl, n- or isopropyl or tert-butyl; a methyl, ethyl or benzyl ester; or an optionally substituted phenyl, phenoxy, cyclopentyl, cyclohexyl, furyl, thienyl, piperidyl, or piperazinyl group.

14. A compound as claimed in any of claims 11 to 13 wherein R_7 represents methyl, ethyl, n- or iso-propyl, n-, sec- or tert-butyl; or when taken

together with the atom or atoms to which they are attached R_6 and R_7 form a monocyclic heterocyclic ring having 5, 6 or 7 ring atoms;

15. A compound as claimed in any of claims 11 to 14 wherein R_1 is H, F,
5 Cl, methyl, methoxy, or methylenedioxy.


16 A compound as claimed in any of claims 11 to 14 wherein R_1 is F, in
the 6-position of the 3-oxo-1,3-dihydro-2H-pyrazolo[4,3-c]cinnolin-2-yl ring
system.

10

17. A compound as claimed in any of claims 11 to 16 wherein R_3 is H, F,
Cl, methyl, methoxy, or methylenedioxy.

18. A compound as claimed in any of claims 11 to 17 wherein X is a bond,
15 or a $-CH_2-$ or $-CH_2CH_2-$ radical.

19. A compound of formula (IC) or a pharmaceutically or veterinarily
acceptable salt, hydrate or solvate thereof:




20 wherein X and R_4 are as specified in any of claims 3, 7 to 10 or 11 to 18.

20. A compound as claimed in claim 18 wherein the radical R_4X- is in the
4-position of the phenyl ring.

25 21. A compound as claimed in claim 19 or claim 20 wherein X is a bond
and R_4 is $-C(=O)NR_6R_7$ wherein R_6 and R_7 are as specified in claim 11, or
claim 13 or 14 respectively.


22. The compound 4-(6-fluoro-3-oxo-1,3-dihydro-pyrazolo[4,3-c]cinnolin-2-yl)-N-(2,2-difluoro-ethyl)-benzamide, of formula (A)



(A)

5 or a pharmaceutically or veterinarily acceptable salt, hydrate or solvate thereof.

23. The compound N-[3-(tert-butyl-methyl-amino)-butyl]-4-(6-fluoro-3-oxo-1,3-dihydro-pyrazolo[4,3-c]cinnolin-2-yl)-benzamide, of formula (B):



(B)

10

or a pharmaceutically or veterinarily acceptable salt, hydrate or solvate thereof.

24. A pharmaceutical or veterinary composition comprising a compound as
15 claimed in any of claims 1 to 23 together with a pharmaceutically or veterinarily acceptable excipient or carrier.

25. A compound as claimed in any of claims 1 to 23 for use in the treatment of conditions which benefit from immunomodulation.

5 26. The use of a compound as claimed in any of claims 1 to 23 in the manufacture of a medicament for the treatment of conditions which benefit from immunomodulation,

10 27. A method of immunomodulation in mammals, including humans, comprising administration to a mammal in need of such treatment an immunomodulatory effective dose of a compound as claimed in any of claims 1 to 23.

15 28. A compound for use as claimed in claim 25, the use as claimed in claim 26 or a method as claimed in claim 27 wherein the immunomodulation is immuno-inhibition.

20 29. A compound for use as claimed in claim 25, the use as claimed in claim 26 or a method as claimed in claim 27 wherein the condition is autoimmune disease, rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosus and psoriasis.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB2004/001008

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D487/04 C07D519/00 A61K31/5025 A61P3/10 A61P17/06
A61P19/02 A61P37/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 03/004495 A (SOERENSEN POUL ; DA GRACA THRIGE DORTHE (DK); ACTIVE BIOTECH AB (SE);) 16 January 2003. (2003-01-16) the whole document	1, 24-29
A	US 4 591 589 A (HUMBERT DANIEL ET AL) 27 May 1986 (1986-05-27) the whole document	1, 24

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

2 June 2004

05.07.2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL-2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Bosma, P

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB2004/001008

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 27-29 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest...

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB2004/001008

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03004495	A	16-01-2003	CA 2451749 A1	16-01-2003
			EP 1409485 A1	21-04-2004
			WO 03004495 A1	16-01-2003
			US 2003022913 A1	30-01-2003

US 4591589	A	27-05-1986	NONE	
